Phase 2 PD-1 Inhibitor Clinical Trials
9 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–9 of 9 trials
Recruiting
Phase 1Phase 2
LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study
Pancreatic CancerPD-1 InhibitorPD-L1+2 more
Zhejiang Provincial People's Hospital10 enrolled1 locationNCT07312422
Recruiting
Phase 2
Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer
TislelizumabPD-1 InhibitorKidney-sparing+2 more
Tianjin Medical University Second Hospital35 enrolled1 locationNCT07233252
Recruiting
Phase 2
Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC
Neoadjuvant TherapyPD-1 InhibitorUpper Tract Urothelial Carcinoma+1 more
Tianjin Medical University Second Hospital35 enrolled1 locationNCT07126119
Recruiting
Phase 2
Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer
Neoadjuvant TherapyTislelizumabPD-1 Inhibitor+3 more
Tianjin Medical University Second Hospital35 enrolled1 locationNCT07125547
Recruiting
Phase 2
Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC
ChemotherapyPD-1 InhibitorInduction Therapy+2 more
The First Affiliated Hospital of Xiamen University208 enrolled3 locationsNCT06811844
Recruiting
Phase 1Phase 2
Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis
Solid TumorsLeptomeningeal MetastasisCTLA4+2 more
Guangzhou Medical University34 enrolled2 locationsNCT06809530
Recruiting
Phase 2
Neoadjuvant Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer
Colorectal Cancer (CRC)PD-1 InhibitorNeoadjuvant Immunotherapy+2 more
Sun Yat-sen University105 enrolled1 locationNCT06903858
Recruiting
Phase 2
Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell
ChemotherapyEsophageal Squamous Cell CarcinomaPD-1 Inhibitor+1 more
Tang-Du Hospital114 enrolled3 locationsNCT06006650
Recruiting
Phase 2
Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma
RadiotherapyCapecitabinePD-1 Inhibitor+1 more
Fifth Affiliated Hospital, Sun Yat-Sen University28 enrolled1 locationNCT05290194